Ziconotide: The Snail Venom Peptide That Became a Pain Medicine

A cone snail supplied the molecular design for an approved pain medicine. The drug is ziconotide, sold as Prialt. Doctors deliver it into the fluid around the spinal cord for selected people with severe chronic pain.

The patients who helped establish its use had already tried other treatments. Their pain remained severe, or the medicines caused problems they could not tolerate. Another way to interrupt pain signals could change what their doctors had left to offer.

Ziconotide reached those patients through an unusual chain of discoveries. Researchers separated components of snail venom, identified a molecule that affected nerve signaling, and reproduced it in the laboratory. Human trials then forced them to solve a further problem: how to obtain useful relief while keeping the treatment tolerable.

The FDA's original review documents that last part in detail. A striking early result led to more questions and another controlled trial before approval.

The marine snail Conus magus hunts fish using venom. Researchers separated its venom into components to examine their effects.

In the discovery work described by Baldomero Olivera and his colleagues, undergraduate researchers helped identify venom components that produced distinct effects in mice. J. Michael McIntosh purified one component from Conus magus. The team worked out its amino acid sequence, and Jean Rivier's laboratory synthesized the peptide. The manufactured version reproduced its biological activity.

A peptide is a chain of amino acids, the units used to build proteins. The molecule that became ziconotide has 25 of them. Its small size still permits a folded structure that binds to a specific target on a nerve cell.

The target was a type of calcium channel. The peptide gave researchers a tool for studying nerve communication.

George Miljanich helped move the work toward a medicine. At Neurex, studies using a labeled version of the peptide found binding in spinal-cord regions involved in pain. That observation gave the team a reason to test whether the molecule could reduce pain.

Pain information has to pass between cells on its way through the nervous system. An electrical signal can reach the end of one nerve, but communication with the next cell requires another step. The first nerve releases chemical messengers across a small gap called a synapse.

Calcium entry helps trigger that release. Ziconotide binds to N-type calcium channels on nerves that carry pain information into the spinal cord. Animal studies support a mechanism in which the drug reduces the release of those messengers. The prescribing information says its exact mechanism in humans has not been established.

In a University of Utah interview, Olivera explains the idea through that handoff: a pain fiber can send an electrical signal while the transfer to the next nerve cell is blocked. It is a useful way to picture the target, though an individual patient's response still has to be measured.

The delivery route follows from where the treatment needs to act. Prialt is given through a pump and catheter into cerebrospinal fluid, the fluid surrounding the brain and spinal cord. This route is called intrathecal administration.

That word belongs near any discussion of the drug's effects. A study result carries information about the molecule and how it reached its target. Changing the route creates a different treatment question.

A trial published in JAMA in 2004 enrolled 111 people with pain related to cancer or AIDS. Researchers assigned intrathecal ziconotide or placebo and adjusted treatment over five to six days.

Among participants with evaluable pain scores, average improvement was 53.1% with ziconotide and 18.1% with placebo. These percentages measure changes in pain ratings.

Half of the evaluable ziconotide group met a more demanding response definition: at least a 30% improvement without an increase or change in opioid therapy. The corresponding figure was 17.5% with placebo.

Adverse events accompanied the benefit. Serious events occurred in 30.6% of the ziconotide safety group and 10% of the placebo group, although those totals include events that were not attributed to the drug. The researchers changed the dosing protocol during enrollment to improve tolerability.

The regulatory review explains why those early results did not settle the approval decision. The sponsor first submitted its application in 1999. The FDA requested further work, including evidence for a regimen patients could use safely and effectively.

Changing treatment during an ongoing trial had left too few participants on the regimen proposed for routine use. Regulators also found that participants at one study site had learned their treatment assignments because of study misconduct. That threatened the protection offered by a blinded comparison.

Serious effects on thinking and behavior were a further concern. The reviewers described confusion, impaired coordination and psychiatric symptoms among the problems seen during development. They needed evidence that a revised approach could produce an acceptable balance of relief and harm.

Those concerns explain the purpose of the next trial. It tested slower increases and lower final doses over three weeks in people whose chronic pain had resisted previous treatment. There were 112 participants assigned to ziconotide and 108 to placebo.

The FDA's analysis found average pain-rating improvements of 12.2% and 5.4%, respectively. For participants with missing final measurements, that analysis assumed no improvement from baseline. The difference favored ziconotide and reached statistical significance.

A second analysis counted people whose pain ratings improved by at least 30%. Eighteen of 112 ziconotide participants met that threshold, compared with 13 of 108 placebo participants. That difference did not reach statistical significance.

These outcomes answer different questions. An average includes each person's degree of change. A response threshold counts only people who cross a chosen cutoff. Seeing both helps a reader judge the size and distribution of a treatment's benefit.

The FDA director's recommendation acknowledged a modest average treatment effect alongside substantial risks. It also described a small group of patients whose severe pain had continued despite available treatment and who obtained meaningful relief.

That clinical setting shaped the decision. A person with persistent, severe pain has a different set of remaining options from someone seeking help for an occasional ache. The review supported approval with clear patient-selection criteria, monitoring and instructions for stopping treatment when needed.

The slower trial did not eliminate nervous-system effects. The review recorded serious adverse events in 12% of ziconotide participants and 9% of placebo participants. Discontinuation because of adverse events was about 5% in each group. Some participants chose to continue into a further study, giving the reviewers additional evidence about whether the treatment was tolerable to people receiving it.

The early and later trials cannot tell us exactly how much changing the regimen altered efficacy. They enrolled different groups under different conditions. A direct comparison of dosing approaches would require a study designed to answer that question.

Current prescribing information retains a boxed warning about severe psychiatric and neurological effects. It rules out use in people with a history of psychosis and requires close monitoring. A pain specialist has to weigh those risks alongside the patient's previous treatments and remaining options.

For someone whose chronic pain remains severe, the useful next step is a review with a pain specialist. Bring a record of previous treatments and what happened with each one. Include the amount of relief and any effects that made treatment hard to continue.

If an intrathecal treatment enters that discussion, ask what improvement would make the procedure worthwhile in your situation. The answer should describe a goal you can recognize in daily life. Ask how the team will assess that goal over time and what would lead them to stop.

Ziconotide's history also gives readers a way to examine the next peptide headline. Find the trial population and follow the treatment all the way to its route of administration. Read the comparison-group result beside the headline number. An average benefit becomes easier to understand when the report also shows how many people achieved a meaningful change.

The cone snail supplied a molecule with a useful biological target. The clinical work established a limited place for it in care: a specialist treatment for people whose severe pain has remained difficult to control.

Which question about pain treatment would you like explained next? Reply and tell me.

1. Safavi-Hemami H, Brogan SE, Olivera BM. Pain Therapeutics from Cone Snail Venoms. Journal of Proteomics, 2019 issue. 2. PRIALT prescribing information, revised May 2025. 3. University of Utah Health. Olivera interview on cone-snail pain research, 2023. 4. Staats PS and colleagues. Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS. JAMA, 2004. 5. FDA CDER. PRIALT medical review, division director's recommendation, December 2004.

For entertainment and education only. Not medical advice. Talk to your doctor before starting anything.